Instructions for Razo (Rabeprazole) 20 mg 30 tablets
English product name
Razo
Release form
T., intestinal-soluble shell, 20 mg: 15 or 30 pcs
Description Razo:
Tablets covered with an intestinal-soluble shell, from light yellow to yellow, round, double-convex, with the marking of red "RB20" on one side; The cross section is white to almost white.
1 tab.
sodium rabeprazole 20 mg
Auxiliary substances: mannitol, hyprolose low-substituted, magnesium oxide heavy, hypromellose (5cps), sodium lauryl sulfate, talc, magnesium stearate.
Shell Composition Razo:
zein, triethyl citrate.
Intestinal-soluble shell composition: The copolymer of methacrylic acid and ethylacrylate [1:1] (copolymer of methacrylic acid (type C)), triethyl citrate, talc.
Shell Composition:
Opadray yellow OY-52945 (5cP hypomellose, titanium dioxide (E171), macrogol 400, iron oxide yellow dye (E172)).
Composition of red ink for the inscription on the tablet: shellac glaze 45%, red charming dye (E129), n-butanol, ethanol denatured, titanium dioxide (E171), propylene glycol, isopropyl alcohol, ammonia solution concentrated 28%.
15 pcs - Blisters of (PVC/AL/PA) foil/aluminium foil (1) - cardboard packs.
15 pcs - Blister Foil/Aluminium Foil (2) - Carton Packs.
15 pcs - high density polyethylene cans (1) - cardboard packs.
30 pcs - high density polyethylene cans (1) - cardboard packs.
ATC codes
A02BC04 Rabeprazole
Clinical-pharmacological groups / Group affiliation
Inhibitor
Antiulcer preparation
Active substance Razo
sodium rabeprazole
Pharmacotherapy group:
Agent for reducing the secretion of gastric glands - proton pump inhibitor
Storage Conditions
The drug Razo should be stored in a place inaccessible to children at a temperature not higher than 25 ° C.
Best before date
Shelf life - two years (in banks), 3 years (in blisters). Do not apply after the expiry date indicated on the package.
Testimony Razo:
- gastric ulcers in the exacerbation phase and anastomosis ulcer;
- duodenal ulcer disease in the exacerbation phase;
- erosive and ulcerative gastroesophageal reflux disease or reflux esophagitis;
- maintenance therapy gastroesophageal reflux disease;
- non-erotic gastroesophageal reflux disease;
- Zollinger-Ellison syndrome and other pathological hypersecretions;
- In combination with appropriate antibacterial therapy for the eradication of Helicobacter pylori in patients with ulcerative
- disease.
Method of use, course and dosage Razo:
The drug Razo is taken inside. The tablets should be swallowed whole, not chewing or chopping. It has been established that neither the time of day nor the ingestion of food affect the activity of rabeprazole.
For gastric ulcers in the exacerbation phase and anastomosis ulcers, it is recommended to take 20 mg per day. Usually, the cure is after six weeks of therapy, but in some cases the duration of treatment can be increased.
For duodenal ulcer disease, it is recommended to take 20 mg once/day per person in the acute phase. The duration of treatment is from 2 to 4 weeks. If necessary, the duration of treatment may be extended by another 4 weeks.
In the treatment of erosive gastroesophageal reflux disease or reflux esophagy it is recommended to take 20 mg once a day. The duration of treatment ranges from four to eight weeks. If necessary, the duration of treatment may be extended by another 8 weeks.
For maintenance therapy, gastroesophageal reflux disease is recommended to take 20 mg once a day. The duration of treatment depends on the patient's condition.
For non-erosive gastroesophageal reflux disease it is recommended to take 20 mg once/day.
If the symptoms do not go away after 4 weeks of treatment, further investigation of the patient should be carried out. Once the symptoms have been treated, the dose of ten mg per day should be taken once per day on demand in order to prevent further symptoms
Use in liver disorders
When prescribing the drug to patients with severe liver failure should be careful.
Terms of Sale
The drug is prescription.
Application in elderly patients
In older patients, no dose correction is required.
Use in children
The use of the preparation in children under 12 years of age is contraindicated.
- Nosology Razo (ICD codes)
- B98.0
- Helicobacter pylori as the cause of diseases classified in other categories
- E16.4
- Gastrine disruption (hypergastrinemia, Zollinger-Ellison syndrome)
- E16.8
- Other specified disorders of internal pancreatic secretion
- K21
- Gastroesophageal reflux
- K21.0
- Gastroesophageal reflux with esophagitis
- K25
- Stomach ulcer
- K26
- Duodenum ulcer
- K27
- Peptic ulcer
Pharmacological effect Razo:
Mechanism of action
Rabeprazole is a class of antisecretory compounds that are chemically substituted for benzimidazole. The preparation inhibits the activity of the enzyme N+-K+-ATP-ase (proton pump), thus blocking the final stage of the synthesis of hydrochloric acid. This effect is dose-dependent and leads to the suppression of both basal and stimulated hydrochloric acid secretion regardless of the stimulus. As a weak base rabeprazole in any doses is quickly absorbed and concentrated in the acidic environment of parietal cells.
Antisecretory activity
After ingestion of rabeprazole in a dose of twenty mg, the antisecretory effect develops within one hour. The suppression of basal and stimulated secretion of hydrochloric acid twenty-three hours after the first dose of sodium rabeprazole is 62% and 82% respectively and continues until 48 h. This duration of pharmacokinetic action is much longer than the predictable T1/2, which is approximately 1 h. This effect may be explained by the binding of the drug to the parietal cell phase of the stomach. The inhibitory effect of sodium rabeprazole on acid secretion reaches the plateau after three days of sodium rabeprazole. If the reception is stopped, secretory activity is restored within 1-2 days.
